Re: MNKD Presents at ADA conference
in response to
by
posted on
Jun 14, 2013 05:40PM
Edit this title from the Fast Facts Section
rt,
You beat me to it!
Medtone vs Gen2 good!
Good dose related linear response to TI.
Max insulin effect is 2h earlier for TI vs subcutaneous insulin.
The mild hypoglycemia is related to the glucose clamp procedure - ie it is non-physiologic. The glucose infusion cannot keep up with the dose of TI. This should not be as big a problem under normal use of the product.
Keep in mind, these are Phase 1 studies that were done earlier as a set-up to the current studies. I'm not aware of the results being released previously.
So in my mind, all is good. We're building momentum to the BIG results!
___________________________________________________________________
From wikipedia:
Euglycemic clamp technique: The plasma insulin concentration is acutely raised and maintained at 100 μU/ml by a continuous infusion of insulin. Meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion. When the steady-state is achieved, the glucose infusion rate equals glucose uptake by all the tissues in the body and is therefore a measure of tissue insulin sensitivity. The hyperinsulinemic clamps are often used to measure insulin resistance.
The glucose clamp technique was developed by Professors Andres and Tobin in 1979.[2] It has since been the gold standard for pharmacodynamic studies in diabetes drug development and diagnostics evaluation.[3]
____________________________________________________________________